Guardant Health (GH) Fundamental Analysis: Revenue, Earnings & Valuation

2.31 / 10

Underperform

GH's fundamental score is weak (2.3/10) with mixed factor performance: Profit-MV and Cash-MV show promise, but Asset-MV and Revenue-MV lag. Gross profit margin is healthy at 64.39%, and net profit/total profit is near 100%, indicating efficient operations. However, the low overall fundamental rating suggests investors should temper expectations for operational growth.

Analysis Checks(7/10)

Revenue-MV

Value-1.11

Score1/3

Weight15.08%

1M Return5.20%

Inventory turnover ratio

Value3.09

Score2/3

Weight-5.72%

1M Return-2.63%

Gross profit margin (%)

Value64.39

Score2/3

Weight3.73%

1M Return1.47%

Profit-MV

Value0.46

Score2/3

Weight22.57%

1M Return7.79%

PB-ROE

Value5.00

Score2/3

Weight31.69%

1M Return10.68%

Current assets turnover ratio

Value0.74

Score1/3

Weight-1.14%

1M Return-0.48%

Fixed assets turnover ratio

Value5.36

Score2/3

Weight0.29%

1M Return0.12%

Asset-MV

Value-0.50

Score0/3

Weight7.71%

1M Return2.94%

Cash-MV

Value-0.07

Score2/3

Weight22.60%

1M Return7.73%

Net profit / Total profit (%)

Value100.16

Score2/3

Weight3.19%

1M Return1.28%

Is GH undervalued or overvalued?

GH scores 2.31/10 on fundamentals and holds a Premium valuation at present. Backed by its 0.00% ROE, -44.18% net margin, -32.19 P/E ratio, -36.22 P/B ratio, and 24.77% earnings growth, these metrics solidify its Underperform investment rating.